DBI 6014
Alternative Names: DI 6014; Fully human monoclonal antibody - DBI 6014Latest Information Update: 23 Feb 2005
At a glance
- Originator Abgenix; Diabetogen Biosciences
- Developer Diabetogen Biosciences
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Type 1 diabetes mellitus
Most Recent Events
- 23 Feb 2005 No development reported - Preclinical for Autoimmune disorders in USA (unspecified route)
- 14 Jan 2003 DPI 6014 is available for licensing [www.diabetogen.com]
- 14 Jan 2003 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route)